Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q15583
UPID:
TGIF1_HUMAN
Alternative names:
5'-TG-3'-interacting factor 1
Alternative UPACC:
Q15583; A6NE42; A6NLU7; F8VZB6; Q6ICR0; Q8N5X9; Q9NRS0
Background:
Homeobox protein TGIF1, also known as 5'-TG-3'-interacting factor 1, plays a pivotal role in brain development by ensuring the correct separation of the forebrain into right and left hemispheres. It functions by binding to retinoid X receptor responsive elements and acting as a transcriptional corepressor of SMAD2, thereby influencing the nodal signaling pathway crucial for forebrain bifurcation and ventral midline structure formation.
Therapeutic significance:
Given its involvement in Holoprosencephaly 4, a genetic disorder characterized by the failure of the forebrain to properly divide, TGIF1 represents a significant target for therapeutic intervention. Understanding the role of Homeobox protein TGIF1 could open doors to potential therapeutic strategies aimed at correcting or mitigating the developmental anomalies associated with this condition.